Skip to main content
SpringerLink
Log in

Latest guidance from NICE

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. NICE recommends simeprevir (Olysio) in combination with peginterferon alfa and ribavirin for treating hepatitis C in final draft guidance. Media Release : 16 Jan 2015. Available from: URL: http://www.nice.org.uk.

  2. NICE. NICE recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack in final draft guidance. Media Release : 23 Jan 2015. Available from: URL: http://www.nice.org.uk.

  3. NICE. NICE set to recommend type 2 diabetes drug empagliflozin. Media Release : 22 Jan 2015. Available from: URL: http://www.nice.org.uk.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Latest guidance from NICE. PharmacoEcon Outcomes News 720, 36 (2015). https://doi.org/10.1007/s40274-015-1875-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-1875-6

Search

Navigation